Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1031-1041

  Purkait, Bidyut ^a   Kumar, Ashish ^a   Nandi, Nilay ^b   Sardar, Abul Hasan ^a   Das, Sushmita ^a   Kumar, Sudeep ^c   Pandey, Krishna ^a   Ravidas, Vidyananda ^a   Kumar, Manish ^a   De, Tripti ^d   Singh, Dharmendra ^a   Das, Pradeep ^a  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,6 DIPHENYL 1,3,5 HEXATRIENE; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; AMPHOTERICIN B; ERGOSTEROL; FLUORESCENT DYE; METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; REACTIVE OXYGEN METABOLITE; S ADENOSYLMETHIONINE; THIOL DERIVATIVE;

ANISOTROPY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; FLUOROMETRY; LD 50; LEISHMANIA DONOVANI; MEMBRANE FLUIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAVENGING SYSTEM; UPREGULATION;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MEMBRANE FLUIDITY; MEMBRANE LIPIDS; PARASITIC SENSITIVITY TESTS; PROTOZOAN PROTEINS; SULFHYDRYL COMPOUNDS;

EID: 84862944418     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00030-11     Document Type: Article

References (57)

1. Arana FE, et al. 1998. Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica. Biochem. Pharmacol. 56:1201-1208. (Pubitemid 28511244)
2. Baginski M, Czub J. 2009. Amphotericin B and its new derivatives - mode of action. Curr. Drug Metab. 10:459-469.
3. Bloch KE. 1983. Sterol structure and membrane function. CRC Crit. Rev. Biochem. 14:47-92.
4. Blum G, et al. 2008. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 52:1553-1555. (Pubitemid 351522034)
5. Bolard J. 1986. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta 864:257-304. (Pubitemid 17228111)
6. Boveris A, et al. 1980. Deficient metabolic utilization of hydrogen peroxide in Trypanosoma cruzi. Biochem. J. 188:643-648.
7. Brajtburg J, Elberg S, Kobayashi GS, Medoff G. 1986. Toxicity and induction of resistance to Listeria monocytogenes infection by amphotericin B in inbred strains of mice. Infect. Immun. 54:303-307. (Pubitemid 17171436)
8. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:183-188. (Pubitemid 20046861)
9. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. 1990. Amphotericin B: delivery system. Antimicrob. Agents Chemother. 34:381-384.
10. Cai C, Zhu H, Chen J. 2004. Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. Biochem. Biophys. Res. Commun. 320:868-874. (Pubitemid 38887223)
11. Castro H, et al. 2002. Complementary antioxidant defense by cytoplasmic and mitochondrial peroxiredoxins in Leishmania infantum. Free Radic. Biol. Med. 33:1552-1562. (Pubitemid 35351599)
12. Croft SL, Sundar S, Fairlamb AH. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126. (Pubitemid 43157649)
13. Demel RA, de Kruyff B. 1976. The function of sterols in membranes. Biochim. Biophys. Acta 457:109-132.
14. Dube A, Singh N, Sundar S, Singh N. 2005. Refractoriness to the treatment of sodium stibogluconate in Indian kalaazar field isolates persists in in-vitro and in-vivo experimental models. Parasitol. Res. 96:216-223. (Pubitemid 40933669)
15. Dutcher JD, Gold W, Pagano JF, Vandepatte J. September 1959. Amphotericin B, its production and its salts. US patent 2,908,611.
16. Ellman GL. 1959. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:70-77.
17. Fairlamb AH, Cerami A. 1992. Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol. 46:695-729.
18. Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A. 1985. Trypanothione: a novel bis (glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 227:1485-1487. (Pubitemid 15146992)
19. Flohé L, Hecht HJ, Steinert P. 1999. Glutathione and trypanothione in parasitic hydroperoxide metabolism. Free Radic. Biol. Med. 27:966-984. (Pubitemid 29507470)
20. Fojo A, Akiyama S, Gottesman MM, Pastan I. 1985. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 45:3002-3007. (Pubitemid 15007164)
21. Galli G, Maroni S. 1967. Mass spectrometric investigations of some unsaturated sterols biosynthetically related to cholesterol. Steroids 10:189-197.
22. Goad LJ, Holtz GG, Jr, Beach DH. 1984. Sterols of Leishmania species. Implications for biosynthesis. Mol. Biochem. Parasitol. 10:161-170. (Pubitemid 14187833)
23. Goad LJ, Holtz GG, Jr, Beach DH. 1985. Sterols of ketoconazole inhibited Leishmania mexicana mexicana promastigotes. Mol. Biochem. Parasitol. 15:257-279. (Pubitemid 15040692)
24. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M. 1997. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 16:3057-3065. (Pubitemid 27234945)
25. Henderson DM, et al. 1992. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol. Cell. Biol. 12:2855-2865.
26. Higgins CF. 1992. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8:67-113. (Pubitemid 23000992)
27. HsuChen C-C, Feingold DS. 1973. Polyene antibiotic action on lecithin liposomes: effect of cholesterol and fatty acyl chains. Biochem. Biophys. Res. Commun. 51:972-978.
28. Jha TK, Giri YN, Singh TK, Jha S. 1995. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. Am. J. Trop. Med. Hyg. 52:536-538.
29. Kawato S, Kinoshita K, Ikegami A. 1977. Dynamic structure of lipid bilayers studied by nanosecond fluorescence techniques. Biochemistry 16:2319-2324. (Pubitemid 8123513)
30. Knights BA. 1967. Identification of plant sterol using combined GLC/mass spectrometry. J. Gas Chromatogr. 5:273-282.
31. Krauth-Siegel RL, Bauer H, Schirmer RH. 2005. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew. Chem. Int. Ed. Engl. 44:690-715. (Pubitemid 40203977)
32. Lamy-Freund MT, Ferreira VFN, Schreier S. 1985. Mechanism of inactivation of the polyene antibiotic amphotericin B: evidence for radical formation in the process of autooxidation. J. Antibiot. (Tokyo) 38:753-757. (Pubitemid 15051150)
33. Lemke A, Kiderlen AF, Kayser O. 2005. Amphotericin B. Appl. Microbiol. Biotechnol. 68:151-162. (Pubitemid 41110936)
34. Lentz BR. 1993. Use of fluorescent probes to monitor order and motions within liposome bilayers. Chem. Phys. Lipids 64:99-116. (Pubitemid 23290868)
35. Lentz BR, Barenholz Y, Thompson TE. 1976. Fluorescence depolarization studies of phase transitions and fluidity in phospholipids bilayers. 1. Single component phosphatidylcholine liposomes. Biochemistry 15:4521-4528.
36. Lin YC, Hsu JY, Chiang SC, Lee ST. 2005. Distinct overexpression of cytosolic and mitochondrial tryparedoxin peroxidases results in preferential detoxification of different oxidants in arsenite-resistant Leishmania amazonensis with and without DNA amplification. Mol. Biochem. Parasitol. 142:66-75. (Pubitemid 40720129)
37. Massey IJ, Djerassi C. 1979. Structural and stereochemical applications of mass spectrometry in the marine sterol field. Synthesis and electron impact induced mass spectral fragmentation of D24 and D24 (28)-3β-hydroxy-D5- sterols. J. Org. Chem. 44:2448-2456.
38. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:352-357. (Pubitemid 28114444)
39. McGonigle S, Dalton JP, James ER. 1998. Peroxidoxins: a new antioxidant family. Parasitol. Today 14:139-145. (Pubitemid 28161005)
40. Mendez S, Nell M, Alunda JM. 1996. Leishmania infantum: infection of macrophages in vitro with promastigotes. Int. J. Parasitol. 26:619-622. (Pubitemid 26273964)
41. Moreira W, Leprohon P, Ouellette M. 2011. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis. doi:10.1038/cddis.2011.83.
42. Mukhopadhyay R, et al. 1996. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. U. S. A. 93:10383-10387. (Pubitemid 26314631)
43. Neal RA, Van BJ, McCoy NG, Iwobi M. 1989. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans. R. Soc. Trop. Med. Hyg. 83:197-198. (Pubitemid 19265563)
44. Nogoceke E, Gommel DU, Kiess M, Kalisz HM, Flohe L. 1997. A unique cascade of oxidoreductases catalyses trypanothione mediated peroxide metabolism in Crithidia fasciculate. Biol. Chem. 378:827-836. (Pubitemid 27388943)
45. Ouellette M, et al. 1998. ABC transporters in Leishmania and their role in drug resistance. Drug Resist. Updat. 1:43-48.
46. Pahissa A. 1997. Amphotericin B. Lipid complex versus liposomes. Which, why, when? Enferm. Infecc. Microbiol. Clin. 15:1-3.
47. Perez-Victoria JM, Parodi-Talice A, Torres C, Gamarro F, Castanys S. 2001. ABC transporters in the protozoan parasite Leishmania. Int. Microbiol. 4:159-166. (Pubitemid 33771678)
48. Pourshafie M, et al. 2004. Cloning of S-adenosyl-L-methionine:C-24- Δ-sterolmethyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes. Antimicrob. Agents Chemother. 48:2409-2414. (Pubitemid 38823404)
49. Ritmeijer K, Dejenie A, Assefa Y. 2006. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin. Infect. Dis. 43:357-364. (Pubitemid 44078909)
50. Seifert K, Croft SL. 2006. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother. 50:73-79. (Pubitemid 43042905)
51. Sinha PK, et al. 2006. Pre-& post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV coinfection. Indian J. Med. Res. 123:197-202. (Pubitemid 43905563)
52. Sokol-Anderson M, et al. 1988. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob. Agents Chemother. 32:702-705.
53. Srivastava P, Prajapati VK, Rai M, Sundar S. 2011. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J. Clin. Microbiol. 49:3088-3091.
54. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. 2007. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356:2571-2581. (Pubitemid 46961002)
55. Tetaud E, et al. 2001. Molecular characterisation of mitochondrial and cytosolic trypanothione-dependent tryparedoxin peroxidases in Trypanosoma brucei. Mol. Biochem. Parasitol. 116:171-183. (Pubitemid 32777826)
56. Urbina JA, Cohen BE, Perozo E, Cornivelli L. 1987. Spin-labeled amphotericin B: synthesis, characterization, biological and spectroscopic properties. Biochim. Biophys. Acta 897:467-473. (Pubitemid 17036301)
57. World Health Organization. 1998. The World Health Report. WHO, Geneva, Switzerland. http://www.who.int/whr/1998/en/whr98-en.pdf.